NASDAQ:EDIT - Get Free Report ) will be announcing its earnings results before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link .
Get Editas Medicine alerts:
Sign Up
Editas Medicine (NASDAQ:EDIT - Get Free Report ) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.29. The business had revenue of $60.00 million for the quarter, compared to the consensus estimate of $4.84 million. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The company's quarterly revenue was up 817.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.88) EPS. On average, analysts expect Editas Medicine to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Editas Medicine Price Performance Editas Medicine stock traded up $0.05 during trading hours on Friday, hitting $5.67. 1,613,186 shares of the stock traded hands, compared to its average volume of 1,811,765. The firm's 50 day moving average price is $7.31 and its 200-day moving average price is $8.26. The stock has a market capitalization of $466.30 million, a price-to-earnings ratio of -2.78 and a beta of 2.09. Editas Medicine has a 1 year low of $5.11 and a 1 year high of $11.91.
Wall Street Analysts Forecast Growth Several brokerages have recently issued reports on EDIT. Citigroup boosted their price objective on Editas Medicine from $11.00 to $16.00 and gave the company a "buy" rating in a report on Thursday, February 29th. StockNews.com raised Editas Medicine from a "sell" rating to a "hold" rating in a report on Friday, March 1st. JPMorgan Chase & Co. boosted their price objective on Editas Medicine from $8.00 to $9.00 and gave the company a "neutral" rating in a report on Tuesday, February 27th. Finally, Barclays boosted their price objective on Editas Medicine from $10.00 to $11.00 and gave the company an "equal weight" rating in a report on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $15.00.
Check Out Our Latest Analysis on Editas Medicine
Insider Buying and Selling In related news, CEO Gilmore Neil O'neill sold 77,824 shares of the company's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $9.42, for a total value of $733,102.08. Following the completion of the transaction, the chief executive officer now owns 327,470 shares of the company's stock, valued at approximately $3,084,767.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . In other Editas Medicine news, CEO Gilmore Neil O'neill sold 77,824 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $9.42, for a total transaction of $733,102.08. Following the completion of the transaction, the chief executive officer now owns 327,470 shares of the company's stock, valued at $3,084,767.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . Also, SVP Baisong Mei sold 20,327 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $9.42, for a total value of $191,480.34. Following the transaction, the senior vice president now directly owns 141,543 shares of the company's stock, valued at approximately $1,333,335.06. The disclosure for this sale can be found here . 1.90% of the stock is currently owned by insiders.
Editas Medicine Company Profile (
Get Free Report )
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
See Also
Before you consider Editas Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.
While Editas Medicine currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
